Sector Alpha Week of 2026-08-05
20-quarter listed-company comparison

Pharma - MNC bulk Drugs Stocks in India

Pharma - MNC bulk Drugs: Abbott India Ltd owns the largest revenue base; Astrazeneca Pharma India Ltd has the fastest current growth.

01 · the index people search for

Nifty Pharma - MNC bulk Drugs Index — Constituents & Performance

The Pharma - MNC bulk Drugs companies below are the listed Indian Pharma - MNC bulk Drugs universe this page tracks — the same constituent set people search for as the Nifty Pharma - MNC bulk Drugs index. Every figure is equal-weighted across those companies, so one large constituent cannot set the reading. Each number carries its own as-of date.

02 · the sector itself · before any single company

How has Pharma - MNC bulk Drugs moved against NIFTY 500?

The line below covers up to 5.2 years and opens on the 5Y view; the buttons cut it shorter. Over the most recent two of them this sector is 0% behind NIFTY 500. Earnings across its companies grew 17% on average over the last four reported quarters. It has been ahead of NIFTY 500 on a rolling three-month view for 6 weeks running.

BREAKING OUT · ahead 6w✓Moving with the index4 of 8 companies ahead of NIFTY 500 by 5% or more over three months

RS ↑6w · 6/8 >200d (+3) · 4/8 lead (+2) · EPS 5/7↑

20030020262025202420232022 298333 TRAILING 12-MONTH EPS · 100 AT THE START0100189Jun 22Dec 22Jun 23Dec 23Jun 24Dec 24Jun 25Dec 25Jun 26Jun 2022 · trailing 12-month earnings per share at 100, against 100 at the start · no comparable year yet · 6 reportingSep 2022 · trailing 12-month earnings per share at 118, against 100 at the start · no comparable year yet · 6 reportingDec 2022 · trailing 12-month earnings per share at 125, against 100 at the start · no comparable year yet · 6 reportingMar 2023 · trailing 12-month earnings per share at 132, against 100 at the start · no comparable year yet · 6 reportingJun 2023 · trailing 12-month earnings per share at 141, against 100 at the start · up 40.9% on a year ago · 6 reportingSep 2023 · trailing 12-month earnings per share at 127, against 100 at the start · up 19.0% on a year ago · 6 reportingDec 2023 · trailing 12-month earnings per share at 130, against 100 at the start · up 10.3% on a year ago · 6 reportingMar 2024 · trailing 12-month earnings per share at 124, against 100 at the start · down 7.2% on a year ago · 7 reportingJun 2024 · trailing 12-month earnings per share at 134, against 100 at the start · down 4.3% on a year ago · 7 reportingSep 2024 · trailing 12-month earnings per share at 115, against 100 at the start · up 9.2% on a year ago · 7 reportingDec 2024 · trailing 12-month earnings per share at 136, against 100 at the start · up 10.4% on a year ago · 7 reportingMar 2025 · trailing 12-month earnings per share at 162, against 100 at the start · up 18.1% on a year ago · 7 reportingJun 2025 · trailing 12-month earnings per share at 180, against 100 at the start · up 40.7% on a year ago · 7 reportingSep 2025 · trailing 12-month earnings per share at 187, against 100 at the start · up 38.4% on a year ago · 7 reportingDec 2025 · trailing 12-month earnings per share at 189, against 100 at the start · up 21.4% on a year ago · 7 reportingMar 2026 · trailing 12-month earnings per share at 170, against 100 at the start · up 11.7% on a year ago · 7 reportingJun 2026 · trailing 12-month earnings per share at 165, against 100 at the start · down 4.9% on a year ago · 3 reporting · thin coverageNot reported yet — earnings trail price by a quarter or two165No earnings on file this far back — the price series reaches further than the filings doNO EARNINGS ON FILE
20030020262025202420232022 298333 TRAILING 12-MONTH EPS · 100 AT THE START0100189Jun 22Jun 23Jun 24Jun 25Jun 26Jun 2022 · trailing 12-month earnings per share at 100, against 100 at the start · no comparable year yet · 6 reportingSep 2022 · trailing 12-month earnings per share at 118, against 100 at the start · no comparable year yet · 6 reportingDec 2022 · trailing 12-month earnings per share at 125, against 100 at the start · no comparable year yet · 6 reportingMar 2023 · trailing 12-month earnings per share at 132, against 100 at the start · no comparable year yet · 6 reportingJun 2023 · trailing 12-month earnings per share at 141, against 100 at the start · up 40.9% on a year ago · 6 reportingSep 2023 · trailing 12-month earnings per share at 127, against 100 at the start · up 19.0% on a year ago · 6 reportingDec 2023 · trailing 12-month earnings per share at 130, against 100 at the start · up 10.3% on a year ago · 6 reportingMar 2024 · trailing 12-month earnings per share at 124, against 100 at the start · down 7.2% on a year ago · 7 reportingJun 2024 · trailing 12-month earnings per share at 134, against 100 at the start · down 4.3% on a year ago · 7 reportingSep 2024 · trailing 12-month earnings per share at 115, against 100 at the start · up 9.2% on a year ago · 7 reportingDec 2024 · trailing 12-month earnings per share at 136, against 100 at the start · up 10.4% on a year ago · 7 reportingMar 2025 · trailing 12-month earnings per share at 162, against 100 at the start · up 18.1% on a year ago · 7 reportingJun 2025 · trailing 12-month earnings per share at 180, against 100 at the start · up 40.7% on a year ago · 7 reportingSep 2025 · trailing 12-month earnings per share at 187, against 100 at the start · up 38.4% on a year ago · 7 reportingDec 2025 · trailing 12-month earnings per share at 189, against 100 at the start · up 21.4% on a year ago · 7 reportingMar 2026 · trailing 12-month earnings per share at 170, against 100 at the start · up 11.7% on a year ago · 7 reportingJun 2026 · trailing 12-month earnings per share at 165, against 100 at the start · down 4.9% on a year ago · 3 reporting · thin coverageNot reported yet — earnings trail price by a quarter or twoNo earnings on file this far back — the price series reaches further than the filings do
Pharma - MNC bulk Drugs, equal-weighted, based at 200 NIFTY 500, same base, same start trailing 12-month earnings per share rising falling

Both lines start at 200 in the same week, so the distance between them is the whole story: the sector line is an equal-weighted index of its 8 companies. The bars underneath are trailing 12-month earnings per share, one bar per reported quarter, each member rebased to 100 at the start and the sector taking the median — so a price line pulling away from flat bars is a re-rating, not earnings. A bar turns red when that figure is lower than the quarter before. Rules are fixed and applied identically everywhere on this site: ahead by 5% or more over three months, or behind by 20% or more over a year while earnings grew 20% or more. Hover any point to read both values and the gap. This is a description of what the numbers did, not advice.

03 · sector relative strength, before individual stocks

Is Pharma - MNC bulk Drugs outperforming NIFTY 500?

Pharma - MNC bulk Drugs has underperformed NIFTY 500 by 5.4% over the last 52 weeks. Over 13 weeks the gap is a lead of 9.9%. 3 of 8 covered companies currently beat NIFTY on Mansfield relative strength, so leadership inside the sector is selective. Novartis India Ltd is the strongest against the sector itself at +42.3%.

+9.9%Sector vs NIFTY 500 · 13 weeks
-5.4%Sector vs NIFTY 500 · 52 weeks
3/8Stocks leading NIFTY 500
2/8Stocks leading sector

Sector metric: 44.5 as of 2026-07-19 · NARROWING · rising.

The central tension: the companies with the most scale are not necessarily the companies creating the most change.

Start with scale. Then earnings trajectory. Then business quality. Only after those three agree should price leadership carry much weight.

Bottom line

Pharma - MNC bulk Drugs has underperformed NIFTY 500 by 5.4% over 52 weeks and 9.9% over 13 weeks. 3 of 8 covered companies beat NIFTY on Mansfield relative strength, while 2 of 8 beat the sector itself. Abbott India Ltd leads with revenue of ₹6,929 crore, based on 8 of 8 comparable companies through Mar 2026.

Companies
8
complete canonical membership
Combined market value
₹1.8 L Cr
Abbott India Ltd
Revenue growing
7/7
positive TTM year-on-year growth
Beating NIFTY 500
3/8
positive Mansfield relative strength
Comparing 5 of 8
04 · research priority, made explicit

4-Factor Sector Score

An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment.

Growth & earnings · 35%Capital efficiency · 25%Valuation · 20%Relative strength · 20%
Procter & Gamble Health Ltd has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 89.6% evidence confidence.
Glaxosmithkline Pharmaceuticals Ltd has stronger price confirmation than earnings confirmation; that is a research prompt, not permission to chase.
How this score is built, and what the marks mean

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1Procter & Gamble Health LtdPGHL 75.3/100Favorable setup90% evidence TURNING 28.7/35 Revenue 15.6% · PAT 30.7% · OPM change 11 pp 88% evidence 21.2/25 ROCE 83.5% · OPM 37% 100% evidence 14.6/20 P/E 33.5× · PEG 0.5 100% evidence 10.8/20 RS sector -2.5% · RS bench 12.6% · 1Y 13.7%11 of 11 weeks ahead 70% evidence
Exact sum: 28.7 + 21.2 + 14.6 + 10.8 = 75.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
2Sanofi Consumer Healthcare India LtdSANOFICONR 61.2/100Mixed-positive evidence67% evidence ASLEEP 26.9/35 Revenue 31% · PAT 33% · OPM change 6 pp 71% evidence 20.9/25 ROCE 89.9% · OPM 38% 76% evidence 9.4/20 P/E 39.9× · PEG — 15% evidence 4.0/20 RS sector -7.1% · RS bench -2.3% · 1Y -7.4%2 of 12 weeks ahead 100% evidence
Exact sum: 26.9 + 20.9 + 9.4 + 4 = 61.2 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -7.1% and the one-year return is -7.4%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
3Pfizer LtdPFIZER 53.7/100Mixed-positive evidence100% evidence TURNING 19.1/35 Revenue 10.6% · PAT -9.2% · OPM change 3 pp 100% evidence 13.8/25 ROCE 24.1% · OPM 38% 100% evidence 18.7/20 P/E 28.7× · PEG 0.73 100% evidence 2.1/20 RS sector -8% · RS bench -3.2% · 1Y -10.2%0 of 12 weeks ahead 100% evidence
Exact sum: 19.1 + 13.8 + 18.7 + 2.1 = 53.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
4Glaxosmithkline Pharmaceuticals LtdGLAXO 49.0/100Mixed-negative evidence96% evidence TURNING 11.8/35 Revenue 1.9% · PAT 11.8% · OPM change 1 pp 88% evidence 17.4/25 ROCE 61.4% · OPM 35% 100% evidence 5.3/20 P/E 46.8× · PEG 6.68 100% evidence 14.5/20 RS sector -1% · RS bench 4.2% · 1Y -15.5%1 of 12 weeks ahead 100% evidence
Exact sum: 11.8 + 17.4 + 5.3 + 14.5 = 49 · Decision use: Price leads the evidence: RS versus the benchmark is 4.2%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
5Abbott India LtdABBOTINDIA 48.8/100Mixed-negative evidence90% evidence TURNING 14.9/35 Revenue 8.1% · PAT 9.7% · OPM change 1 pp 88% evidence 15.7/25 ROCE 44.8% · OPM 28% 100% evidence 7.9/20 P/E 38.2× · PEG 2.56 100% evidence 10.3/20 RS sector -0.7% · RS bench -2.8% · 1Y -17.7%5 of 10 weeks ahead 70% evidence
Exact sum: 14.9 + 15.7 + 7.9 + 10.3 = 48.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
6Novartis India LtdNOVARTIND 46.8/100Mixed-negative evidence100% evidence LEADER 13.3/35 Revenue 5.4% · PAT -4.9% · OPM change 3 pp 100% evidence 6.9/25 ROCE 16.2% · OPM 34% 100% evidence 6.6/20 P/E 38.8× · PEG 1.96 100% evidence 20.0/20 RS sector 42.3% · RS bench 49% · 1Y 51.6%12 of 12 weeks ahead 100% evidence
Exact sum: 13.3 + 6.9 + 6.6 + 20 = 46.8 · Decision use: Price leads the evidence: RS versus the benchmark is 49%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
7Astrazeneca Pharma India LtdASTRAZEN 40.7/100Mixed-negative evidence83% evidence ASLEEP 17.0/35 Revenue 32.6% · PAT 63.5% · OPM change -7 pp 88% evidence 8.6/25 ROCE 29.3% · OPM 11% 100% evidence 4.3/20 P/E 106× · PEG 3.95 65% evidence 10.8/20 RS sector 2.3% · RS bench -7.8% · 1Y -8.7%0 of 10 weeks ahead 70% evidence
Exact sum: 17 + 8.6 + 4.3 + 10.8 = 40.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
8Sanofi India LtdSANOFI 49.6/100Thin evidence · provisional40% evidence ASLEEP 17.7/35 Revenue — · PAT — · OPM change 2 pp 5% evidence 15.0/25 ROCE 49.2% · OPM 23% 57% evidence 13.9/20 P/E 17.3× · PEG — 50% evidence 3.0/20 RS sector -26.7% · RS bench -18.8% · 1Y -43.3%0 of 10 weeks ahead 70% evidence
Exact sum: 17.7 + 15 + 13.9 + 3 = 49.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
05 · what price has already done

Market action

Novartis India Ltd has the strongest one-year price move in Pharma - MNC bulk Drugs at +51.6%. It also leads on Mansfield relative strength against NIFTY at +49%. 3 of 8 covered companies are above zero on that measure. Every line covers 313 weekly closes through 2026-07-31.

Price and relative strength

Every company, the sector's own index and NIFTY 500 all start level on the left edge of the window, so only the distance between the lines counts — the highest line has risen the most since then, and the chart at the top of this page is drawn the same way. It opens on one year; the buttons beside it stretch that to three or five.

06 · compare level, then change

Revenue Scale & Growth Durability

Abbott India Ltd has the highest Revenue among the 8 Pharma - MNC bulk Drugs companies compared here, at ₹6,929 crore. Glaxosmithkline Pharmaceuticals Ltd is next at ₹3,821 crore. Astrazeneca Pharma India Ltd has the highest Revenue growth at 32.6%, so level and change sit with different companies. Its Revenue series carries 19 reported observations across the 20-quarter window.

What the numbers say: Abbott India Ltd is the scale leader at ₹6,929 crore, 81.3% ahead of Glaxosmithkline Pharmaceuticals Ltd. Astrazeneca Pharma India Ltd's growth is 32.6% from a ₹2,276 crore base, with 19 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale.

LeaderAbbott India Ltd · ₹6,929 crore
Gap81.3% versus #2 · Glaxosmithkline Pharmaceuticals Ltd
Persistence8/8 recent comparable periods
Coverage8/8 companies · 135 observations

Investor read: Abbott India Ltd is the scale benchmark; Astrazeneca Pharma India Ltd is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns.

This conclusion weakens if: Abbott India Ltd's growth falls below Astrazeneca Pharma India Ltd's for two consecutive comparable reports while operating margin also compresses.

Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.
Revenuelargest
1Abbott India Ltd ABBOTINDIA₹6.9K Cr
2Glaxosmithkline Pharmaceuticals Ltd GLAXO₹3.8K Cr
3Pfizer Ltd PFIZER₹2.6K Cr
4Astrazeneca Pharma India Ltd ASTRAZEN₹2.3K Cr
5Sanofi India Ltd SANOFI · older report₹2.0K Cr
Revenue growthfastest growers
1Astrazeneca Pharma India Ltd ASTRAZEN33%
2Sanofi Consumer Healthcare India Ltd SANOFICONR31%
3Procter & Gamble Health Ltd PGHL16%
4Pfizer Ltd PFIZER11%
5Abbott India Ltd ABBOTINDIA8.1%
Revenue · company comparison
8/8 level · 7/8 change

On every company-comparison chart on this page: solid lines show level, dotted lines show change when “Both” is selected, and a missing report breaks the line rather than being invented.

All-company data · latest reported quarter

In every all-company table on this page, each figure is the company’s latest single reported quarter. The rankings above them use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.

CompanyRevenueRevenue growthReported
Abbott India Ltd ABBOTINDIA₹1.7K Cr6.5%Mar 2026
Glaxosmithkline Pharmaceuticals Ltd GLAXO₹995 Cr2.2%Mar 2026
Pfizer Ltd PFIZER₹653 Cr8.3%Jun 2026
Astrazeneca Pharma India Ltd ASTRAZEN₹579 Cr21%Mar 2026
Sanofi India Ltd SANOFI₹515 Cr9.8%Dec 2024
Procter & Gamble Health Ltd PGHL₹370 Cr19%Mar 2026
Sanofi Consumer Healthcare India Ltd SANOFICONR₹236 Cr6.8%Jun 2026
Novartis India Ltd NOVARTIND₹104 Cr18%Jun 2026
Full 20-quarter history · every available company

Revenue · reported quarter history

Abbott India Ltd · ABBOTINDIA

₹1.2K Cr
₹1.2K Cr
₹1.2K Cr
₹1.3K Cr
₹1.4K Cr
₹1.3K Cr
₹1.3K Cr
₹1.5K Cr
₹1.5K Cr
₹1.4K Cr
₹1.4K Cr
₹1.6K Cr
₹1.6K Cr
₹1.6K Cr
₹1.6K Cr
₹1.7K Cr
₹1.8K Cr
₹1.7K Cr
₹1.7K Cr
—

Astrazeneca Pharma India Ltd · ASTRAZEN

₹198 Cr
₹201 Cr
₹232 Cr
₹232 Cr
₹236 Cr
₹250 Cr
₹285 Cr
₹295 Cr
₹311 Cr
₹306 Cr
₹383 Cr
₹388 Cr
₹408 Cr
₹440 Cr
₹480 Cr
₹526 Cr
₹559 Cr
₹612 Cr
₹579 Cr
—

Glaxosmithkline Pharmaceuticals Ltd · GLAXO

₹1.0K Cr
₹816 Cr
₹810 Cr
₹745 Cr
₹917 Cr
₹802 Cr
₹787 Cr
₹762 Cr
₹957 Cr
₹805 Cr
₹930 Cr
₹815 Cr
₹1.0K Cr
₹949 Cr
₹974 Cr
₹805 Cr
₹980 Cr
₹1.0K Cr
₹995 Cr
—

Novartis India Ltd · NOVARTIND

₹104 Cr
₹99 Cr
₹98 Cr
₹121 Cr
₹102 Cr
₹80 Cr
₹76 Cr
₹91 Cr
₹79 Cr
₹85 Cr
₹81 Cr
₹92 Cr
₹87 Cr
₹93 Cr
₹84 Cr
₹88 Cr
₹90 Cr
₹86 Cr
₹91 Cr
₹104 Cr

Pfizer Ltd · PFIZER

₹636 Cr
₹676 Cr
₹550 Cr
₹593 Cr
₹637 Cr
₹622 Cr
₹573 Cr
₹531 Cr
₹575 Cr
₹540 Cr
₹547 Cr
₹563 Cr
₹589 Cr
₹538 Cr
₹592 Cr
₹603 Cr
₹642 Cr
₹645 Cr
₹629 Cr
₹653 Cr

Procter & Gamble Health Ltd · PGHL

₹273 Cr
₹278 Cr
₹268 Cr
₹296 Cr
₹298 Cr
₹310 Cr
₹321 Cr
₹301 Cr
₹305 Cr
₹310 Cr
₹252 Cr
₹284 Cr
₹313 Cr
₹310 Cr
₹311 Cr
₹339 Cr
₹325 Cr
₹374 Cr
₹370 Cr
—

Sanofi Consumer Healthcare India Ltd · SANOFICONR

—
—
—
—
—
—
—
—
₹210 Cr
₹225 Cr
₹222 Cr
₹172 Cr
₹160 Cr
₹171 Cr
₹173 Cr
₹221 Cr
₹234 Cr
₹251 Cr
₹229 Cr
₹236 Cr

Sanofi India Ltd · SANOFI

—
—
—
—
—
—
—
₹515 Cr
₹491 Cr
₹469 Cr
₹511 Cr
₹464 Cr
₹524 Cr
₹515 Cr
—
—
—
—
—
—

Revenue growth · reported quarter history

Abbott India Ltd · ABBOTINDIA

—
—
—
7.1%
13%
8.0%
7.5%
13%
8.3%
8.7%
7.2%
5.3%
9.3%
12%
12%
12%
7.6%
6.8%
6.5%
—

Astrazeneca Pharma India Ltd · ASTRAZEN

—
—
—
33%
19%
24%
23%
27%
32%
22%
34%
32%
31%
44%
25%
36%
37%
39%
21%
—

Glaxosmithkline Pharmaceuticals Ltd · GLAXO

—
—
—
-5.7%
-9.2%
-1.7%
-2.8%
2.3%
4.4%
0.4%
18%
7.0%
5.6%
18%
4.7%
-1.2%
-3.1%
9.7%
2.2%
—

Novartis India Ltd · NOVARTIND

—
—
—
23%
-1.9%
-19%
-22%
-25%
-23%
6.3%
6.6%
1.1%
10%
9.4%
3.7%
-4.4%
3.5%
-7.5%
8.3%
18%

Pfizer Ltd · PFIZER

—
—
—
-21%
0.2%
-8.0%
4.2%
-10%
-9.7%
-13%
-4.5%
6.0%
2.4%
-0.4%
8.2%
7.1%
9.0%
20%
6.3%
8.3%

Procter & Gamble Health Ltd · PGHL

—
—
—
3.9%
9.2%
12%
20%
1.7%
2.4%
0.0%
-22%
-5.7%
2.6%
0.0%
23%
19%
3.8%
21%
19%
—

Sanofi Consumer Healthcare India Ltd · SANOFICONR

—
—
—
—
—
—
—
—
—
—
—
—
-24%
-24%
-22%
28%
46%
47%
32%
6.8%

Sanofi India Ltd · SANOFI

—
—
—
—
—
—
—
—
—
—
—
-9.9%
6.7%
9.8%
—
—
—
—
—
—
07 · compare level, then change

Operating Economics & Margin Trend

Pfizer Ltd has the highest OPM among the 8 Pharma - MNC bulk Drugs companies compared here, at 38%. Procter & Gamble Health Ltd has the highest Margin change at +11 percentage points, so level and change sit with different companies. 8 of 8 companies report a comparable reading, the latest through Jun 2026.

What the numbers say: Pfizer Ltd leads opm at 38%; Procter & Gamble Health Ltd leads margin change at +11 percentage points.

LeaderPfizer Ltd · 38%
Gap0% versus #2 · Sanofi Consumer Healthcare India Ltd
Persistence5/8 recent comparable periods
Coverage8/8 companies · 142 observations

Investor read: Pfizer Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current margin change signal.

Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.
OPMhighest
1Pfizer Ltd PFIZER38%
2Sanofi Consumer Healthcare India Ltd SANOFICONR38%
3Procter & Gamble Health Ltd PGHL37%
4Glaxosmithkline Pharmaceuticals Ltd GLAXO35%
5Novartis India Ltd NOVARTIND34%
Margin changefastest expanders
1Procter & Gamble Health Ltd PGHL+11.0 pp
2Sanofi Consumer Healthcare India Ltd SANOFICONR+6.0 pp
3Novartis India Ltd NOVARTIND+3.0 pp
4Pfizer Ltd PFIZER+3.0 pp
5Sanofi India Ltd SANOFI · older report+2.0 pp
Operating margin · company comparison
8/8 level · 8/8 change
All-company data · latest reported quarter
CompanyOPMMargin changeReported
Pfizer Ltd PFIZER38%+3.0 ppJun 2026
Sanofi Consumer Healthcare India Ltd SANOFICONR38%+6.0 ppJun 2026
Procter & Gamble Health Ltd PGHL37%+11.0 ppMar 2026
Glaxosmithkline Pharmaceuticals Ltd GLAXO35%+1.0 ppMar 2026
Novartis India Ltd NOVARTIND34%+3.0 ppJun 2026
Abbott India Ltd ABBOTINDIA28%+1.0 ppMar 2026
Sanofi India Ltd SANOFI23%+2.0 ppDec 2024
Astrazeneca Pharma India Ltd ASTRAZEN11%−7.0 ppMar 2026
Full 20-quarter history · every available company

OPM · reported quarter history

Abbott India Ltd · ABBOTINDIA

21%
22%
23%
21%
25%
24%
21%
24%
25%
27%
23%
25%
27%
27%
27%
26%
29%
27%
28%
—

Astrazeneca Pharma India Ltd · ASTRAZEN

9.1%
7.3%
16%
12%
17%
15%
21%
23%
17%
4.9%
13%
10%
13%
17%
18%
15%
13%
7.0%
11%
—

Glaxosmithkline Pharmaceuticals Ltd · GLAXO

27%
24%
22%
20%
28%
29%
22%
19%
30%
27%
28%
28%
32%
31%
34%
31%
34%
36%
35%
—

Novartis India Ltd · NOVARTIND

6.8%
6.6%
5.7%
26%
16%
10%
12%
19%
21%
23%
14%
26%
21%
28%
29%
31%
26%
26%
23%
34%

Pfizer Ltd · PFIZER

30%
29%
30%
32%
36%
33%
32%
21%
32%
28%
35%
32%
32%
27%
38%
35%
36%
35%
38%
38%

Procter & Gamble Health Ltd · PGHL

29%
22%
26%
20%
31%
35%
25%
15%
29%
33%
27%
17%
36%
40%
26%
27%
37%
30%
37%
—

Sanofi Consumer Healthcare India Ltd · SANOFICONR

—
—
—
—
—
—
—
—
45%
40%
37%
37%
39%
36%
37%
32%
36%
36%
39%
38%

Sanofi India Ltd · SANOFI

26%
18%
28%
23%
26%
25%
31%
24%
23%
21%
27%
25%
23%
23%
—
—
—
—
—
—

Margin change · reported quarter history

Abbott India Ltd · ABBOTINDIA

−1.6 pp
−0.1 pp
+4.6 pp
−1.1 pp
+3.6 pp
+2.0 pp
−2.4 pp
+3.3 pp
+0.1 pp
+3.0 pp
+2.0 pp
+1.0 pp
+2.0 pp
0.0 pp
+4.0 pp
+1.0 pp
+2.0 pp
0.0 pp
+1.0 pp
—

Astrazeneca Pharma India Ltd · ASTRAZEN

−8.0 pp
−8.0 pp
−2.9 pp
+3.1 pp
+8.2 pp
+7.7 pp
+4.6 pp
+11.0 pp
−0.3 pp
−10.1 pp
−8.0 pp
−13.0 pp
−4.0 pp
+12.1 pp
+5.0 pp
+5.0 pp
0.0 pp
−10.0 pp
−7.0 pp
—

Glaxosmithkline Pharmaceuticals Ltd · GLAXO

+4.1 pp
+1.4 pp
+0.6 pp
+1.5 pp
+0.6 pp
+4.8 pp
+0.4 pp
−1.0 pp
+2.0 pp
−2.0 pp
+6.0 pp
+9.0 pp
+2.0 pp
+4.0 pp
+6.0 pp
+3.0 pp
+2.0 pp
+5.0 pp
+1.0 pp
—

Novartis India Ltd · NOVARTIND

−3.9 pp
+9.7 pp
−9.7 pp
+18.3 pp
+9.3 pp
+3.4 pp
+6.3 pp
−7.3 pp
+4.9 pp
+13.0 pp
+2.0 pp
+7.0 pp
0.0 pp
+5.0 pp
+15.0 pp
+5.0 pp
+5.0 pp
−2.0 pp
−6.0 pp
+3.0 pp

Pfizer Ltd · PFIZER

−4.4 pp
−4.3 pp
+6.6 pp
−5.8 pp
+6.6 pp
+4.1 pp
+1.9 pp
−11.4 pp
−4.4 pp
−5.0 pp
+3.0 pp
+11.0 pp
0.0 pp
−1.0 pp
+3.0 pp
+3.0 pp
+4.0 pp
+8.0 pp
0.0 pp
+3.0 pp

Procter & Gamble Health Ltd · PGHL

−1.0 pp
−14.7 pp
+11.7 pp
+3.0 pp
+1.9 pp
+12.8 pp
−0.7 pp
−5.0 pp
−1.5 pp
−2.0 pp
+2.0 pp
+2.0 pp
+7.0 pp
+7.0 pp
−1.0 pp
+10.0 pp
+1.0 pp
−10.0 pp
+11.0 pp
—

Sanofi Consumer Healthcare India Ltd · SANOFICONR

—
—
—
—
—
—
—
—
—
—
—
—
−6.0 pp
−4.0 pp
0.0 pp
−5.0 pp
−3.0 pp
0.0 pp
+2.0 pp
+6.0 pp

Sanofi India Ltd · SANOFI

−1.6 pp
−4.7 pp
+1.4 pp
−8.3 pp
−0.1 pp
+6.4 pp
+3.7 pp
+1.0 pp
−3.3 pp
−3.8 pp
−4.2 pp
+1.0 pp
0.0 pp
+2.0 pp
—
—
—
—
—
—
08 · compare level, then change

Profit Scale & Acceleration

Abbott India Ltd has the highest Net profit among the 8 Pharma - MNC bulk Drugs companies compared here, at ₹1,552 crore. Glaxosmithkline Pharmaceuticals Ltd is next at ₹1,036 crore. Astrazeneca Pharma India Ltd has the highest Profit growth at 63.5%, so level and change sit with different companies.

What the numbers say: Abbott India Ltd leads with ₹1,552 crore of TTM profit, 49.8% above Glaxosmithkline Pharmaceuticals Ltd. Astrazeneca Pharma India Ltd shows 63.5% growth from a ₹188 crore profit base. Compare the size of the base and persistence before ranking acceleration above profit scale.

LeaderAbbott India Ltd · ₹1,552 crore
Gap49.8% versus #2 · Glaxosmithkline Pharmaceuticals Ltd
Persistence8/8 recent comparable periods
Coverage8/8 companies · 135 observations

Investor read: Abbott India Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.

Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.
Net profitlargest
1Abbott India Ltd ABBOTINDIA₹1.6K Cr
2Glaxosmithkline Pharmaceuticals Ltd GLAXO₹1.0K Cr
3Pfizer Ltd PFIZER₹735 Cr
4Sanofi India Ltd SANOFI · older report₹413 Cr
5Procter & Gamble Health Ltd PGHL₹328 Cr
Profit growthfastest growers
1Astrazeneca Pharma India Ltd ASTRAZEN64%
2Sanofi Consumer Healthcare India Ltd SANOFICONR33%
3Procter & Gamble Health Ltd PGHL31%
4Glaxosmithkline Pharmaceuticals Ltd GLAXO12%
5Abbott India Ltd ABBOTINDIA9.7%
Net profit · company comparison
8/8 level · 7/8 change
All-company data · latest reported quarter
CompanyNet profitProfit growthReported
Abbott India Ltd ABBOTINDIA₹395 Cr7.6%Mar 2026
Glaxosmithkline Pharmaceuticals Ltd GLAXO₹278 Cr5.7%Mar 2026
Pfizer Ltd PFIZER₹204 Cr6.3%Jun 2026
Procter & Gamble Health Ltd PGHL₹95 Cr56%Mar 2026
Sanofi India Ltd SANOFI₹91 Cr-34%Dec 2024
Sanofi Consumer Healthcare India Ltd SANOFICONR₹69 Cr13%Jun 2026
Astrazeneca Pharma India Ltd ASTRAZEN₹45 Cr-22%Mar 2026
Novartis India Ltd NOVARTIND₹32 Cr14%Jun 2026
Full 20-quarter history · every available company

Net profit · reported quarter history

Abbott India Ltd · ABBOTINDIA

₹192 Cr
₹199 Cr
₹211 Cr
₹206 Cr
₹266 Cr
₹247 Cr
₹231 Cr
₹290 Cr
₹313 Cr
₹311 Cr
₹287 Cr
₹328 Cr
₹359 Cr
₹361 Cr
₹367 Cr
₹366 Cr
₹415 Cr
₹376 Cr
₹395 Cr
—

Astrazeneca Pharma India Ltd · ASTRAZEN

₹12 Cr
₹11 Cr
₹28 Cr
₹20 Cr
₹33 Cr
₹29 Cr
₹17 Cr
₹54 Cr
₹52 Cr
₹16 Cr
₹39 Cr
₹-12 Cr
₹38 Cr
₹31 Cr
₹58 Cr
₹56 Cr
₹54 Cr
₹33 Cr
₹45 Cr
—

Glaxosmithkline Pharmaceuticals Ltd · GLAXO

₹204 Cr
₹150 Cr
₹1.2K Cr
₹119 Cr
₹193 Cr
₹165 Cr
₹133 Cr
₹132 Cr
₹218 Cr
₹46 Cr
₹194 Cr
₹182 Cr
₹252 Cr
₹230 Cr
₹263 Cr
₹205 Cr
₹257 Cr
₹296 Cr
₹278 Cr
—

Novartis India Ltd · NOVARTIND

₹7 Cr
₹6 Cr
₹-23 Cr
₹52 Cr
₹18 Cr
₹8 Cr
₹25 Cr
₹20 Cr
₹24 Cr
₹27 Cr
₹15 Cr
₹26 Cr
₹20 Cr
₹25 Cr
₹29 Cr
₹28 Cr
₹24 Cr
₹16 Cr
₹25 Cr
₹32 Cr

Pfizer Ltd · PFIZER

₹143 Cr
₹144 Cr
₹126 Cr
₹33 Cr
₹311 Cr
₹151 Cr
₹130 Cr
₹94 Cr
₹149 Cr
₹130 Cr
₹179 Cr
₹151 Cr
₹158 Cr
₹128 Cr
₹331 Cr
₹192 Cr
₹189 Cr
₹142 Cr
₹200 Cr
₹204 Cr

Procter & Gamble Health Ltd · PGHL

₹55 Cr
₹45 Cr
₹51 Cr
₹41 Cr
₹64 Cr
₹77 Cr
₹59 Cr
₹30 Cr
₹66 Cr
₹72 Cr
₹47 Cr
₹17 Cr
₹82 Cr
₹91 Cr
₹61 Cr
₹66 Cr
₹89 Cr
₹78 Cr
₹95 Cr
—

Sanofi Consumer Healthcare India Ltd · SANOFICONR

—
—
—
—
—
—
—
—
₹71 Cr
₹68 Cr
₹63 Cr
₹29 Cr
₹45 Cr
₹44 Cr
₹50 Cr
₹61 Cr
₹63 Cr
₹66 Cr
₹68 Cr
₹69 Cr

Sanofi India Ltd · SANOFI

—
—
—
—
—
—
—
₹123 Cr
₹152 Cr
₹138 Cr
₹137 Cr
₹103 Cr
₹82 Cr
₹91 Cr
—
—
—
—
—
—

Profit growth · reported quarter history

Abbott India Ltd · ABBOTINDIA

—
—
—
5.1%
39%
24%
9.5%
41%
18%
26%
24%
13%
15%
16%
28%
12%
16%
4.2%
7.6%
—

Astrazeneca Pharma India Ltd · ASTRAZEN

—
—
—
100%
175%
164%
-39%
170%
58%
-45%
129%
-122%
-27%
94%
49%
—
42%
6.5%
-22%
—

Glaxosmithkline Pharmaceuticals Ltd · GLAXO

—
—
—
-1.7%
-5.4%
10%
-89%
11%
13%
-72%
46%
38%
16%
400%
36%
13%
2.0%
29%
5.7%
—

Novartis India Ltd · NOVARTIND

—
—
—
767%
157%
33%
—
-62%
33%
238%
-40%
30%
-17%
-7.4%
93%
7.7%
20%
-36%
-14%
14%

Pfizer Ltd · PFIZER

—
—
—
-84%
117%
4.9%
3.2%
185%
-52%
-14%
38%
61%
6.0%
-1.5%
85%
27%
20%
11%
-40%
6.3%

Procter & Gamble Health Ltd · PGHL

—
—
—
21%
16%
71%
16%
-27%
3.1%
-6.5%
-20%
-43%
24%
26%
30%
288%
8.5%
-14%
56%
—

Sanofi Consumer Healthcare India Ltd · SANOFICONR

—
—
—
—
—
—
—
—
—
—
—
—
-37%
-35%
-21%
110%
40%
50%
36%
13%

Sanofi India Ltd · SANOFI

—
—
—
—
—
—
—
—
—
—
—
-16%
-46%
-34%
—
—
—
—
—
—
09 · compare level, then change

Return On Capital Employed

Sanofi Consumer Healthcare India Ltd has the highest ROCE among the 8 Pharma - MNC bulk Drugs companies compared here, at 89.9%. Procter & Gamble Health Ltd is next at 83.5%. Procter & Gamble Health Ltd has the highest ROCE change at +14.6 percentage points, so level and change sit with different companies.

What the numbers say: Sanofi Consumer Healthcare India Ltd leads ROCE at 89.9%, 6.4 percentage points above Procter & Gamble Health Ltd. Procter & Gamble Health Ltd has the strongest latest improvement at +14.6 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability.

LeaderSanofi Consumer Healthcare India Ltd · 89.9%
Gap7.7% versus #2 · Procter & Gamble Health Ltd
PersistenceNot enough history
Coverage8/8 companies · 89 observations

Investor read: Sanofi Consumer Healthcare India Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current roce change signal.

ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.
ROCEhighest
1Sanofi Consumer Healthcare India Ltd SANOFICONR90%
2Procter & Gamble Health Ltd PGHL84%
3Glaxosmithkline Pharmaceuticals Ltd GLAXO61%
4Sanofi India Ltd SANOFI · older report49%
5Abbott India Ltd ABBOTINDIA45%
ROCE changefastest improvers
1Procter & Gamble Health Ltd PGHL+14.6 pp
2Pfizer Ltd PFIZER+4.0 pp
3Abbott India Ltd ABBOTINDIA0.0 pp
4Novartis India Ltd NOVARTIND0.0 pp
5Glaxosmithkline Pharmaceuticals Ltd GLAXO−1.6 pp
Return on capital · company comparison
8/8 level · 6/8 change

Withheld from this chart: Sanofi Consumer Healthcare India Ltd (SANOFICONR) — its two data sources disagree by up to 132% on reported income across 11 comparable periods, so its derived ratios are withheld; Sanofi India Ltd (SANOFI) — its two data sources disagree by up to 45% on reported income across 6 comparable periods, so its derived ratios are withheld. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.

All-company data · latest reported quarter
CompanyROCEROCE changeReported
Procter & Gamble Health Ltd PGHL74%+14.6 ppMar 2026
Glaxosmithkline Pharmaceuticals Ltd GLAXO49%−1.6 ppMar 2026
Abbott India Ltd ABBOTINDIA36%0.0 ppMar 2026
Astrazeneca Pharma India Ltd ASTRAZEN23%−3.2 ppMar 2026
Pfizer Ltd PFIZER20%+4.0 ppJun 2026
Novartis India Ltd NOVARTIND11%0.0 ppJun 2026
Full 20-quarter history · every available company

ROCE · reported quarter history

Abbott India Ltd · ABBOTINDIA

35%
—
34%
—
38%
—
34%
—
39%
50%
36%
47%
40%
52%
36%
47%
41%
52%
36%
—

Astrazeneca Pharma India Ltd · ASTRAZEN

—
—
13%
—
19%
—
25%
—
30%
31%
24%
20%
18%
18%
26%
32%
33%
35%
23%
—

Glaxosmithkline Pharmaceuticals Ltd · GLAXO

37%
—
25%
—
42%
—
37%
—
43%
42%
41%
44%
50%
63%
51%
61%
58%
71%
49%
—

Novartis India Ltd · NOVARTIND

2.2%
—
3.2%
—
7.5%
—
7.3%
—
6.4%
16%
8.2%
16%
10%
16%
11%
17%
12%
18%
11%
—

Pfizer Ltd · PFIZER

26%
—
24%
—
22%
—
21%
—
18%
21%
16%
24%
17%
23%
16%
27%
19%
29%
20%
—

Procter & Gamble Health Ltd · PGHL

—
30%
—
37%
—
38%
—
37%
44%
37%
36%
33%
36%
38%
59%
56%
58%
52%
74%
—

ROCE change · reported quarter history

Abbott India Ltd · ABBOTINDIA

—
—
—
—
+3.3 pp
—
+0.2 pp
—
+0.5 pp
—
+2.0 pp
—
+1.6 pp
+1.7 pp
+0.1 pp
+0.2 pp
+0.5 pp
−0.3 pp
0.0 pp
—

Astrazeneca Pharma India Ltd · ASTRAZEN

—
—
—
—
—
—
+11.6 pp
—
+11.0 pp
—
−1.0 pp
—
−12.3 pp
−12.4 pp
+2.6 pp
+12.2 pp
+15.0 pp
+16.1 pp
−3.2 pp
—

Glaxosmithkline Pharmaceuticals Ltd · GLAXO

—
—
—
—
+4.9 pp
—
+12.3 pp
—
+1.0 pp
—
+3.9 pp
—
+6.8 pp
+21.0 pp
+9.3 pp
+17.1 pp
+8.1 pp
+8.4 pp
−1.6 pp
—

Novartis India Ltd · NOVARTIND

—
—
—
—
+5.3 pp
—
+4.1 pp
—
−1.1 pp
—
+0.9 pp
—
+3.9 pp
−0.5 pp
+2.9 pp
+0.8 pp
+1.5 pp
+1.6 pp
0.0 pp
—

Pfizer Ltd · PFIZER

—
—
—
—
−3.7 pp
—
−2.6 pp
—
−4.3 pp
—
−5.4 pp
—
−0.7 pp
+2.3 pp
0.0 pp
+3.1 pp
+2.2 pp
+5.9 pp
+4.0 pp
—

Procter & Gamble Health Ltd · PGHL

—
—
—
—
—
+7.7 pp
—
+0.1 pp
—
−1.1 pp
—
−3.7 pp
−7.3 pp
+0.7 pp
+23.2 pp
+22.9 pp
+22.2 pp
+14.5 pp
+14.6 pp
—
10 · compare level, then change

Valuation Against Growth & Quality

Procter & Gamble Health Ltd has the lowest PEG among the 8 Pharma - MNC bulk Drugs companies compared here, at 0.5×. Pfizer Ltd is next at 0.73×. Sanofi India Ltd has the lowest P/E at 17.3×, so level and change sit with different companies. 6 of 8 companies report a comparable reading, the latest through Mar 2026.

What the numbers say: Procter & Gamble Health Ltd has the lowest comparable PEG at 0.5×, 31.5% below Pfizer Ltd. Only 6 of 8 companies have earnings and growth steady enough for the ratio to mean anything, so no broad “cheapest stock” conclusion is defensible unless the current multiple, own-history position and growth durability agree.

LeaderProcter & Gamble Health Ltd · 0.5×
Gap31.5% versus #2 · Pfizer Ltd
Persistence0/8 recent comparable periods
Coverage6/8 companies · 60 observations

Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.

This conclusion weakens if: The next two comparable reports reverse the current p/e signal.

PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.
PEGlowest PEG
1Procter & Gamble Health Ltd PGHL0.5
2Pfizer Ltd PFIZER0.7
3Novartis India Ltd NOVARTIND2.0
4Abbott India Ltd ABBOTINDIA2.6
5Astrazeneca Pharma India Ltd ASTRAZEN4.0
P/Elowest P/E
1Sanofi India Ltd SANOFI · older report17.3
2Pfizer Ltd PFIZER28.7
3Procter & Gamble Health Ltd PGHL33.5
4Abbott India Ltd ABBOTINDIA38.2
5Novartis India Ltd NOVARTIND38.8
Valuation · company comparison
6/8 level · 8/8 change
All-company data · latest reported quarter
CompanyPEGP/EReported
Glaxosmithkline Pharmaceuticals Ltd GLAXO6.738.1Mar 2026
Astrazeneca Pharma India Ltd ASTRAZEN4.095.3Mar 2026
Abbott India Ltd ABBOTINDIA2.636.4Mar 2026
Novartis India Ltd NOVARTIND2.038.1Jun 2026
Pfizer Ltd PFIZER0.727.0Jun 2026
Procter & Gamble Health Ltd PGHL0.527.5Mar 2026
Sanofi Consumer Healthcare India Ltd SANOFICONR—42.1Jun 2026
Sanofi India Ltd SANOFI—39.8Dec 2024
Full 20-quarter history · every available company

PEG · reported quarter history

Abbott India Ltd · ABBOTINDIA

12.1
4.6
3.3
3.1
3.0
2.2
5.3
1.3
1.7
2.0
2.1
3.8
2.5
2.6
3.0
3.0
2.5
2.3
2.6
—

Astrazeneca Pharma India Ltd · ASTRAZEN

4.0
—
—
—
—
—
—
—
—
—
—
—
—
—
25.3
—
3.1
16.8
4.0
—

Glaxosmithkline Pharmaceuticals Ltd · GLAXO

—
—
—
—
—
5.8
—
—
0.9
—
1.1
6.0
3.7
1.9
1.6
2.0
—
2.3
6.7
—

Novartis India Ltd · NOVARTIND

—
—
—
—
—
—
—
—
—
—
—
1.2
1.2
—
—
3.3
1.6
—
2.0
—

Pfizer Ltd · PFIZER

4.5
2.3
1.4
—
—
—
—
—
—
—
1.0
—
7.0
2.5
—
—
2.7
2.1
1.2
0.7

Procter & Gamble Health Ltd · PGHL

—
—
—
—
4.0
2.8
0.6
1.2
1.9
1.8
—
—
—
—
4.2
1.8
0.8
0.9
0.5
—

P/E · reported quarter history

Abbott India Ltd · ABBOTINDIA

63.8
57.7
46.0
48.0
50.3
51.5
50.5
52.4
47.6
44.9
50.3
48.9
50.2
48.4
48.9
52.5
43.5
40.7
36.4
—

Astrazeneca Pharma India Ltd · ASTRAZEN

90.8
109.8
107.3
111.0
108.8
89.5
73.9
70.7
68.3
79.9
83.5
104.3
137.1
123.5
128.4
117.0
104.2
96.0
95.3
—

Glaxosmithkline Pharmaceuticals Ltd · GLAXO

63.8
63.1
55.0
61.1
58.8
53.9
51.6
40.9
42.9
50.5
51.4
68.4
59.3
48.1
57.1
66.7
47.8
43.8
38.1
—

Novartis India Ltd · NOVARTIND

88.8
85.9
51.3
35.0
18.7
16.5
13.6
19.4
24.9
24.9
26.6
32.0
31.7
26.5
22.5
24.5
21.0
18.2
24.9
38.1

Pfizer Ltd · PFIZER

45.6
39.6
34.3
30.6
35.1
34.8
26.9
28.5
31.7
36.5
37.8
38.0
44.3
36.4
29.8
41.0
33.4
32.7
28.2
27.0

Procter & Gamble Health Ltd · PGHL

50.6
51.2
46.8
36.3
35.4
32.7
33.4
36.2
37.0
35.5
34.5
39.2
43.7
38.7
34.8
37.8
34.7
30.5
27.5
—

Sanofi Consumer Healthcare India Ltd · SANOFICONR

—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
57.3
56.5
51.2
40.0
42.1

Sanofi India Ltd · SANOFI

—
—
—
—
—
—
—
—
—
—
32.5
44.0
44.1
39.8
—
—
—
—
—
—
11 · before the conclusion, check the blind spots

What can make this comparison misleading?

This Pharma - MNC bulk Drugs comparison names 6 specific ways its own evidence can mislead, all listed below. 1 of the 8 companies reports on an older date than the sector's freshest reporters, so its rank is marked stale. 2 have second-feed figures withheld because the two sources disagree. A high growth rate can still be a low-base artefact.

Keep these limits visible

  • A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason.
  • A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment.
  • The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed.
  • An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
  • 1 company has an older fundamental reporting date than the sector’s freshest reporters; its rank carries a stale marker.
  • 2 companies are missing from the second-feed metrics by decision, not by absence: the two sources disagree, so nothing from the second is drawn. Read those rows as narrower evidence, never as a weaker business.
12 · evidence and freshness

How was this comparison built?

This comparison is built from the reported filings of 8 Pharma - MNC bulk Drugs companies, normalized to a common ₹ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Jun 2026 and market data through 2026-07-31.

FundamentalsThrough Jun 2026 · up to 20 quarters per company
Market dataThrough 2026-07-31 · weekly price and relative-strength history
Derived metricsGrowth, changes and PEG are calculated only when their inputs are comparable.
Score confidenceMissing and stale evidence reduces confidence and pulls the 0–100 research-priority score toward neutral.
Source standing6 cross-checked · 0 unverified · 2 withheld, of 8 graded companies.
How a second data feed is admitted, and what happens when it disagrees

A second feed is read only after its reported income is matched against the primary source on at least three overlapping periods. Where the two agree the figures fill silently. Where there is too little shared history to compare, the figures are still drawn — they are the only evidence there is — and marked ⚠ unverified everywhere they appear. Where the two are known to disagree, nothing from the second feed is drawn and the affected company is named under the chart it is missing from.

13 · questions investors ask, short speakable answers

Pharma - MNC bulk Drugs company comparison FAQs

These 24 answers restate the Pharma - MNC bulk Drugs comparison above in question form. Every one is computed from the same 8 companies and the same reported filings as the rankings and charts, current through Jun 2026. Price and relative-strength answers run through 2026-07-31. Nothing here is estimated, and none of it is a recommendation.

Is the Pharma - MNC bulk Drugs sector outperforming NIFTY 500?

Pharma - MNC bulk Drugs has underperformed NIFTY 500 by 5.4% over 52 weeks and 9.9% over 13 weeks. 3 of 8 covered companies beat NIFTY on Mansfield relative strength, while 2 of 8 beat the sector itself.

Which Pharma - MNC bulk Drugs company is largest by revenue?

Abbott India Ltd leads with revenue of ₹6,929 crore, based on 8 of 8 comparable companies through Mar 2026.

Which Pharma - MNC bulk Drugs company is growing fastest?

Astrazeneca Pharma India Ltd has the fastest current revenue growth at 32.6%, across 7 of 8 comparable companies.

Which Pharma - MNC bulk Drugs company has the strongest 4-Factor Sector Score?

Procter & Gamble Health Ltd ranks first at 75.3/100 with 89.6% evidence confidence. The score prioritizes research; it is not a buy recommendation.

Which Pharma - MNC bulk Drugs company has the lowest comparable PEG?

Procter & Gamble Health Ltd has the lowest comparable PEG at 0.5, among 6 of 8 companies whose earnings and growth are steady enough for the ratio to mean anything.

How much history does this Pharma - MNC bulk Drugs comparison include?

The page compares up to 20 reported quarters per company for fundamentals, returns and valuation, ending Jun 2026. Missing observations remain blank rather than being estimated.

How is the 4-Factor Sector Score calculated?

The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral.

What is the Nifty Pharma - MNC bulk Drugs index?

The Nifty Pharma - MNC bulk Drugs index tracks India's listed Pharma - MNC bulk Drugs companies as a single basket. This page follows the same 8 companies and equal-weights them, so every company's weekly return counts once whatever it is worth, and the reading belongs to the Pharma - MNC bulk Drugs sector rather than to its largest constituent. Figures are as of Jun 2026.

Which are the best Pharma - MNC bulk Drugs stocks in India?

Ranked by this page's four-factor score, Procter & Gamble Health Ltd places first among 8 listed Pharma - MNC bulk Drugs companies, followed by Sanofi Consumer Healthcare India Ltd. That is a ranking of published data — earnings, quality, valuation and market behaviour as of Jun 2026 — and not a recommendation; Sector Alpha is not registered with SEBI as an investment adviser.

How many Pharma - MNC bulk Drugs stocks are listed in India?

This comparison covers 8 listed Pharma - MNC bulk Drugs companies in India, each above the size floor the site applies, with 20 quarters of reported figures per company where the filings exist. The full ranked list is on this page, as of Jun 2026.

Which Pharma - MNC bulk Drugs company is the biggest?

Abbott India Ltd is the largest, with trailing-twelve-month revenue of ₹6,929 crore, ahead of Glaxosmithkline Pharmaceuticals Ltd at ₹3,821 crore. That covers 8 of 8 companies with comparable reporting through Mar 2026.

Which Pharma - MNC bulk Drugs company has the best profit margins?

Pfizer Ltd has the highest operating margin at 38%, from 8 of 8 comparable companies. Procter & Gamble Health Ltd shows the biggest recent improvement, at +11 percentage points. A high margin matters most when it is holding or rising, not when it is peaking.

Which Pharma - MNC bulk Drugs company makes the most profit?

Abbott India Ltd earns the most, at ₹1,552 crore of trailing-twelve-month net profit, from 8 of 8 comparable companies. Astrazeneca Pharma India Ltd has the fastest profit growth at 63.5%, though growth off a small or recovering profit base overstates how much has actually changed.

Which Pharma - MNC bulk Drugs company earns the highest return on capital?

Sanofi Consumer Healthcare India Ltd leads on return on capital employed at 89.9%, across 8 of 8 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year.

Which Pharma - MNC bulk Drugs stock is the cheapest?

On PEG — where a LOWER number is cheaper — Procter & Gamble Health Ltd screens cheapest at 0.5×. Only 6 of 8 companies have earnings and growth steady enough for the ratio to mean anything, so this is not a sector-wide "cheapest stock" verdict. Cheap on a multiple is a reason to investigate, never a reason to buy on its own.

Is the Pharma - MNC bulk Drugs sector beating the market?

Pharma - MNC bulk Drugs has underperformed NIFTY 500 by 5.4% over the last 52 weeks and 9.9% over 13 weeks, measured on an equal-weight index of its current members. Inside the sector, 3 of 8 covered companies are beating the market on their own. Sector strength does not transfer evenly to every stock in it.

Which Pharma - MNC bulk Drugs stock has the strongest price momentum?

Novartis India Ltd has the strongest relative strength against NIFTY 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all.

Which Pharma - MNC bulk Drugs company scores highest for research priority?

Procter & Gamble Health Ltd scores 75.3 out of 100 with 89.6% evidence confidence, from 28.7 points on growth and earnings, 21.2 on capital efficiency, 14.6 on valuation and 10.8 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research.

How many Pharma - MNC bulk Drugs companies does this comparison cover, and over what period?

It compares 8 listed companies over up to 20 reported quarters of fundamentals, ending Jun 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data.

What is the total market cap of the Pharma - MNC bulk Drugs sector?

The 8 Pharma - MNC bulk Drugs companies on this page carry ₹1,79,396 crore of combined market value. Abbott India Ltd is the largest at ₹59,075 crore, about 33% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-08-05.

What is the Pharma - MNC bulk Drugs sector's P/E ratio?

The median price-to-earnings ratio across the 8 Pharma - MNC bulk Drugs companies on this page is 38.8×, measured on the 8 that report a comparable figure. A sector-level history for this multiple is not held here, so this is a cross-section of today, not a comparison with the sector’s own past. Figures are as of 2026-08-05.

How is the Pharma - MNC bulk Drugs sector performing?

3 of the 8 covered Pharma - MNC bulk Drugs companies are beating NIFTY 500 on Mansfield relative strength. The sector itself is 5.4% behind NIFTY 500 over 52 weeks on an equal-weight index of its current members. Readings are as of 2026-08-05.

Why are some values on this page blank?

A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad.

Is this investment advice?

No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI